Inflammatory disorders and atherosclerosis: new therapeutic approaches.

Current pharmaceutical design

Volumn 17, Issue 37, 2011, Pages 4111-4120

  Charakida, Marietta ^a   O'Neil, Frank ^b   Masi, Stefano ^b   Papageorgiou, Nikolaos ^b   Tousoulis, Dimitris ^b  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ANIMAL; APOPTOSIS; ATHEROSCLEROSIS; CHRONIC DISEASE; DRUG EFFECT; GENETICS; HUMAN; IMMUNOLOGY; INFLAMMATION; METABOLISM; OXIDATIVE STRESS; PATHOLOGY; REVIEW; RISK FACTOR; VASCULAR ENDOTHELIUM;

ANIMALS; ANTI-INFLAMMATORY AGENTS; APOPTOSIS; ATHEROSCLEROSIS; CHRONIC DISEASE; ENDOTHELIUM, VASCULAR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; OXIDATIVE STRESS; RISK FACTORS;

EID: 84861308648     PISSN: None     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211798764807     Document Type: Review

References (0)